Find a Research Expert

Experts
 Menu

William M Gallagher

Institution

University College Dublin

Contact

Subjects

Biochemistry

Details
Publications 148
As first author 7
As last author 48
Unique topics 978
Collaborations 214
Patents 5
Sources 12
Are you William M Gallagher? Click here to provide feedback on your profile.
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
Earlier
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
Earlier

2019

Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents.
2019

PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer
2018

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
2018

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
2018

Role of serum response factor expression in prostate cancer biochemical recurrence.
2018

What are the mechanisms that enable the reciprocal involvement of seldom heard groups in health and social care research? A rapid realist review protocol
2017

A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.
2017

Absolute Quantification of Toxicological Biomarkers via Mass Spectrometry.
2017

BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.
2017

Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma.
2017

Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.
2017

Epigenetics of malignant melanoma.
2017

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
2017

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
2017

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
2017

The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways.
2017

Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification.
2017

Vitamin D receptor as a target for breast cancer therapy.
2016

A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.
2016

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.
2016

Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology.
2016

Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.
2016

Circulating MicroRNAs in Cancer.
2016

De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.
2016

Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
2016

Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer
2016

Functionalization of emissive conjugated polymer nanoparticles by coprecipitation: consequences for particle photophysics and colloidal properties.
2016

Master Transcriptional Regulators in Cancer: Discovery via Reverse Engineering Approaches and Subsequent Validation.
2016

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
2016

Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer
2016

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
2016

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
2016

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
2015

Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer.
2015

Commercialized biomarkers: new horizons in prostate cancer diagnostics.
2015

Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients.
2015

FKBPL: a marker of good prognosis in breast cancer.
2015

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
2015

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
2015

Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time.
2015

Prognostic and predictive biomarkers in melanoma: an update.
2015

Relationship between serum response factor and androgen receptor in prostate cancer.
2015

The Role of Exosomes in Breast Cancer.
2015

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.
2014

A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer.
2014

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.
2014

Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers.
2014

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.
2014

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.
2014

The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases
2014

The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides.
2014

microRNAs: a new class of breast cancer biomarkers.
2013

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
2013

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.
2013

MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach.
2013

The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.
2013

miRNA dysregulation in breast cancer.
2012

Development of a pharmaceutical hepatotoxicity biomarker panel using a discovery to targeted proteomics approach.
2012

Identification of transcription factors associated with castration-resistance: Is the serum responsive factor a potential therapeutic target?
2012

Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
2012

The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate.
2012

Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond.
2012

miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.
2011

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
2011

Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma.
2011

Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice.
2011

Identification of cell surface-specific markers to target human nucleus pulposus cells: expression of carbonic anhydrase XII varies with age and degeneration.
2011

Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods
2011

Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation.
2011

The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer.
2011

The hydroxylase inhibitor DMOG attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B-1 cells.
2011

Truncated HER2: implications for HER2-targeted therapeutics.
2010

Absolute quantification of toxicological biomarkers by multiple reaction monitoring.
2010

An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia.
2010

Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.
2010

Differential proteomics incorporating iTRAQ labeling and multi-dimensional separations.
2010

Effect of surface wettability and topography on the adhesion of osteosarcoma cells on plasma-modified polystyrene.
2010

Examination of cell-host-biomaterial interactions via high-throughput technologies : a re-appraisal
2010

Examination of cell-host-biomaterial interactions via high-throughput technologies: A re-appraisal.
2010

Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro.
2010

Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods.
2010

Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo.
2010

Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis.
2010

PKCzeta regulates cell polarisation and proliferation restriction during mammary acinus formation.
2010

Standardization of models and methods used to assess nanoparticles in cardiovascular applications.
2010

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
2010

The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility
2010

Tissue microarrays and digital image analysis.
2010

Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis.
2010

Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
2010

Use of SELDI MS to discover and identify potential biomarkers of toxicity in InnoMed PredTox: a multi-site, multi-compound study.
2010

Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
2009

Bioluminescent imaging: a critical tool in pre-clinical oncology research.
2009

High sensitivity cytokine detection in acute coronary syndrome reveals up-regulation of interferon gamma and interleukin-10 post myocardial infarction.
2009

Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
2009

JAM-A expression positively correlates with poor prognosis in breast cancer patients.
2009

JAM-A expression positively correlates with poor prognosis in breast cancer patients.
2009

Omic profiling for drug safety assessment: current trends and public-private partnerships.
2009

Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy.
2009

Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification.
2009

Surface-induced cell signaling events control actin rearrangements and motility.
2009

Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.
2008

Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.
2008

Applications of SELDI-MS technology in oncology.
2008

Automated image analysis in histopathology: a valuable tool in medical diagnostics.
2008

High-throughput proteomics detection of novel splice isoforms in human platelets.
2008

Identification and functional validation of therapeutic targets for malignant melanoma.
2008

Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques.
2008

Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
2008

Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
2008

Selected highlights of the Third Annual Biomarkers Congress: from discovery to validation in the drug development arena.
2007

Breast cancer proteomics: clinical perspectives.
2007

CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer.
2007

Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy.
2007

Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.
2007

Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: an initial report from the PredTox group.
2007

DNA microarray-based transcriptomic profiling of an isogenic cell culture model of breast tumour cell invasion.
2007

Formalin-fixed paraffin-embedded clinical tissues show spurious copy number changes in array-CGH profiles.
2007

Formalin-fixed paraffin-embedded clinical tissues show spurious copy number changes in array-CGH profiles.
2007

Molecular links between mammary gland development and breast cancer.
2007

Real-time quantitative reverse transcriptase-polymerase chain reaction analysis of melanoma progression-associated genes.
2007

Use of proteomics for the discovery of early markers of drug toxicity.
2006

Functional interrogation of breast cancer: from models to drugs.
2006

Molecular basis of cell-biomaterial interaction: insights gained from transcriptomic and proteomic studies.
2006

Novel "plum pudding" gels as potential drug-eluting stent coatings: controlled release of fluvastatin.
2006

Novel method to prepare morphologically rich polymeric surfaces for biomedical applications via phase separation and arrest of microgel particles.
2006

Protein tyrosine phosphatases, new targets for cancer therapy.
2006

Proteomic analysis of factors released from p21-overexpressing tumour cells.
2006

TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells.
2006

The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line.
2005

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia.
2005

Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response.
2005

Fibulins and cancer: friend or foe?
2005

Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies.
2005

Supramolecular photonic therapeutic agents.
2005

Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction.
2005

The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line.
2004

In vitro demonstration of the heavy-atom effect for photodynamic therapy.
2004

Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems.
2004

Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride.
2004

Poly(N-isopropylacrylamide) copolymer films as vehicles for the sustained delivery of proteins to vascular endothelial cells.
2003

Elevated expression and altered processing of fibulin-1 protein in human breast cancer.
2003

Extended delivery of the antimitotic agent colchicine from thermoresponsive N-isopropylacrylamide-based copolymer films to human vascular smooth muscle cells.
2003

Interaction of soft condensed materials with living cells: phenotype/transcriptome correlations for the hydrophobic effect.
2003

Poly(N-isopropylacrylamide) co-polymer films as potential vehicles for delivery of an antimitotic agent to vascular smooth muscle cells.
2002

Synthesis of BF2 chelates of tetraarylazadipyrromethenes and evidence for their photodynamic therapeutic behaviour.
2001

Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues.
1996

Structural basis of p21H-ras molecular switch inhibition by a neutralizing antibody.

These arethe12 unique sources for William M Gallagher's 148 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Dublin City University 12
Ireland -> Dublin City University -> PubMed 12
Ireland -> Maynooth University 1
Ireland -> National University of Ireland Galway 4
Ireland -> National University of Ireland Galway -> PubMed 3
Ireland -> Royal College of Surgeons in Ireland 21
Ireland -> Royal College of Surgeons in Ireland -> PubMed 14
Ireland -> Trinity College Dublin 9
Ireland -> Trinity College Dublin -> PubMed 5
Ireland -> University College Cork 1
Ireland -> University College Dublin 103
Ireland -> University College Dublin -> PubMed 96
Jul 15, 2014

Conjugate of a cationic antimicrobial peptide and of a fatty acid for use as an anti-cancer agent
+
Jun 10, 2009

METHOD AND SYSTEM FOR IMAGE ANALYSIS
+
Nov 22, 2007

METHODS AND COMPOSITIONS FOR IDENTIFYING AND USING P21-REGULATED PROTEINS
+
Sep 7, 2006

MARKERS FOR MELANOMA
+
Oct 1, 2003

COMPOUNDS USEFUL AS PHOTODYNAMIC THERAPEUTIC AGENTS
+

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.